ZA200207933B - Stabilized pharmaceutical compositions containing calcium channel blockers. - Google Patents
Stabilized pharmaceutical compositions containing calcium channel blockers. Download PDFInfo
- Publication number
- ZA200207933B ZA200207933B ZA200207933A ZA200207933A ZA200207933B ZA 200207933 B ZA200207933 B ZA 200207933B ZA 200207933 A ZA200207933 A ZA 200207933A ZA 200207933 A ZA200207933 A ZA 200207933A ZA 200207933 B ZA200207933 B ZA 200207933B
- Authority
- ZA
- South Africa
- Prior art keywords
- group
- pharmaceutical composition
- composition according
- methyl
- phenyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 39
- 239000000480 calcium channel blocker Substances 0.000 title claims description 14
- 229940127291 Calcium channel antagonist Drugs 0.000 title 1
- -1 carbamoyloxy Chemical group 0.000 claims description 129
- 125000001153 fluoro group Chemical group F* 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 125000003277 amino group Chemical group 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 6
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 claims 5
- 229950004646 azelnidipine Drugs 0.000 claims 5
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims 4
- 229960002992 barnidipine Drugs 0.000 claims 4
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 claims 4
- 229960004916 benidipine Drugs 0.000 claims 4
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 claims 4
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 claims 4
- 229960003963 manidipine Drugs 0.000 claims 4
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 claims 4
- 229960001783 nicardipine Drugs 0.000 claims 4
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 claims 3
- XTFPDGZNWTZCMF-DHZHZOJOSA-N 3-o-methyl 5-o-[(e)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 XTFPDGZNWTZCMF-DHZHZOJOSA-N 0.000 claims 3
- 229960000528 amlodipine Drugs 0.000 claims 3
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 3
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims 3
- 229960000227 nisoldipine Drugs 0.000 claims 3
- 229960005425 nitrendipine Drugs 0.000 claims 3
- 229950004891 pranidipine Drugs 0.000 claims 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 3
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 claims 2
- WTOVRSWDBLIFHU-UHFFFAOYSA-N Lemildipine Chemical compound COC(=O)C1=C(C)NC(COC(N)=O)=C(C(=O)OC(C)C)C1C1=CC=CC(Cl)=C1Cl WTOVRSWDBLIFHU-UHFFFAOYSA-N 0.000 claims 2
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims 2
- 150000008041 alkali metal carbonates Chemical class 0.000 claims 2
- 229910000318 alkali metal phosphate Inorganic materials 0.000 claims 2
- 229910052910 alkali metal silicate Inorganic materials 0.000 claims 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 2
- 229910000287 alkaline earth metal oxide Inorganic materials 0.000 claims 2
- 229910052915 alkaline earth metal silicate Inorganic materials 0.000 claims 2
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 claims 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims 2
- 239000000378 calcium silicate Substances 0.000 claims 2
- 229910052918 calcium silicate Inorganic materials 0.000 claims 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims 2
- 229960003020 cilnidipine Drugs 0.000 claims 2
- 229960003580 felodipine Drugs 0.000 claims 2
- 229950001530 lemildipine Drugs 0.000 claims 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 2
- 229960001597 nifedipine Drugs 0.000 claims 2
- 229960005366 nilvadipine Drugs 0.000 claims 2
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 claims 1
- ZGRIPYHIFXGCHR-UHFFFAOYSA-N 3-o-[2-[(4-fluorophenyl)methyl-methylamino]ethyl] 5-o-propan-2-yl 4-(1,3-benzodioxol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound C=1C=CC=2OCOC=2C=1C1C(C(=O)OC(C)C)=C(C)NC(C)=C1C(=O)OCCN(C)CC1=CC=C(F)C=C1 ZGRIPYHIFXGCHR-UHFFFAOYSA-N 0.000 claims 1
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 claims 1
- HERJJROLHRDFEX-UHFFFAOYSA-N [AlH3].[Si](O)(O)(O)O Chemical compound [AlH3].[Si](O)(O)(O)O HERJJROLHRDFEX-UHFFFAOYSA-N 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims 1
- 229910000316 alkaline earth metal phosphate Inorganic materials 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 229950007556 aranidipine Drugs 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims 1
- 239000000292 calcium oxide Substances 0.000 claims 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims 1
- 229950003102 efonidipine Drugs 0.000 claims 1
- 229950010020 elgodipine Drugs 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 claims 1
- 239000000395 magnesium oxide Substances 0.000 claims 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 1
- 239000000391 magnesium silicate Substances 0.000 claims 1
- 229910052919 magnesium silicate Inorganic materials 0.000 claims 1
- 235000019792 magnesium silicate Nutrition 0.000 claims 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000108850 | 2000-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200207933B true ZA200207933B (en) | 2003-11-28 |
Family
ID=18621626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200207933A ZA200207933B (en) | 2000-04-11 | 2002-10-02 | Stabilized pharmaceutical compositions containing calcium channel blockers. |
Country Status (23)
Country | Link |
---|---|
US (4) | US20030073670A1 (hu) |
EP (1) | EP1285655B1 (hu) |
JP (1) | JP2009143923A (hu) |
KR (1) | KR100756565B1 (hu) |
CN (1) | CN100450483C (hu) |
AT (1) | ATE363281T1 (hu) |
AU (2) | AU2001246883B2 (hu) |
BR (1) | BR0109991A (hu) |
CA (1) | CA2405046C (hu) |
CZ (1) | CZ301790B6 (hu) |
DE (1) | DE60128683T2 (hu) |
ES (1) | ES2287110T3 (hu) |
HK (1) | HK1050324A1 (hu) |
HU (1) | HUP0300444A3 (hu) |
IL (2) | IL152021A0 (hu) |
MX (1) | MXPA02010040A (hu) |
NO (1) | NO329943B1 (hu) |
NZ (1) | NZ521853A (hu) |
PL (1) | PL201513B1 (hu) |
RU (1) | RU2239432C2 (hu) |
TW (1) | TWI246921B (hu) |
WO (1) | WO2001076598A1 (hu) |
ZA (1) | ZA200207933B (hu) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3595765B2 (ja) * | 2000-09-27 | 2004-12-02 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロースを含む乾式直打用基剤 |
MXPA05006885A (es) * | 2002-12-24 | 2005-08-16 | Sankyo Co | Derivado de dihidropiridina opticamente activo. |
AU2004208615C1 (en) * | 2003-01-31 | 2010-05-13 | Daiichi Sankyo Company, Limited | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
DK1628663T3 (da) | 2003-05-15 | 2010-03-08 | Roskamp Res Llc | Fremgangsmåde til fremstilling af medikamenter til reduktion af amyloid-aflejring, amyloid-neurotoksicitet og mikrogliose |
CN1762354B (zh) * | 2004-10-18 | 2010-07-28 | 上海药明康德新药开发有限公司 | 一种含有钙阻滞剂的稳定药物组合物 |
US20070042049A1 (en) * | 2005-06-03 | 2007-02-22 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
EP1931340A2 (en) * | 2005-06-15 | 2008-06-18 | Elan Pharma International Limited | Nanoparticulate azelnidipine formulations |
KR20130135994A (ko) * | 2005-06-27 | 2013-12-11 | 다이이찌 산쿄 가부시키가이샤 | 안지오텐신 ⅱ 수용체 길항제 및 칼슘 채널 차단제를 함유한 약학 제제 |
TW200736245A (en) * | 2005-11-29 | 2007-10-01 | Sankyo Co | Acid addition salts of optically active dihydropyridine derivatives |
TW200806648A (en) * | 2005-11-29 | 2008-02-01 | Sankyo Co | Acid addition salts of dihydropyridine derivatives |
CN101103979B (zh) * | 2006-07-14 | 2010-12-08 | 海南盛科生命科学研究院 | 一种阿折地平药物组合物及其制备方法 |
TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
GB0709541D0 (en) * | 2007-05-17 | 2007-06-27 | Jagotec Ag | Pharmaceutical excipient |
JP2008290989A (ja) * | 2007-05-28 | 2008-12-04 | Ube Ind Ltd | ジヒドロピリジン誘導体の酸付加塩を含有する医薬 |
DK2214666T3 (da) | 2007-10-05 | 2014-01-27 | Alzheimer S Inst Of America Inc | Fremgangsmåde til reducering af amyloid-afsætning, amyloid-neurotoksicitet og mikrogliose med (-)-nilvadipin-enantiomer |
EP2307022A4 (en) * | 2007-10-31 | 2011-08-24 | Equitech Corp | ENHANCED NON-STEROID ANTI-INFLAMMATORY FORMULATIONS (NSAIDs) |
NZ594513A (en) | 2009-03-04 | 2013-10-25 | Orexo Ab | Abuse resistant formulation |
EP2427177B1 (en) | 2009-05-08 | 2018-03-28 | Emplicure AB | Composition for sustained drug delivery comprising geopolymeric binder |
CA2809927C (en) | 2010-09-07 | 2019-08-20 | Orexo Ab | A transdermal drug administration device |
JP5917034B2 (ja) * | 2011-07-15 | 2016-05-11 | ニプロ株式会社 | カルシウムブロッカーを含有する固形医薬組成物 |
US8679547B2 (en) * | 2011-10-20 | 2014-03-25 | Tomita Pharmaceutical Co., Ltd. | Method for manufacturing calcium silicate based composition |
CN102921008B (zh) * | 2012-11-16 | 2014-01-01 | 南京正大天晴制药有限公司 | 一种含有钙阻滞剂的药物组合物 |
CN104473888B (zh) * | 2014-11-20 | 2017-01-18 | 南京正大天晴制药有限公司 | 一种阿折地平的药物组合物 |
JP6462625B2 (ja) * | 2016-04-06 | 2019-01-30 | ニプロ株式会社 | カルシウムブロッカーを含有する錠剤 |
JP6426115B2 (ja) * | 2016-04-06 | 2018-11-21 | ニプロ株式会社 | カルシウムブロッカーを含有する固形医薬組成物 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1670827C3 (de) * | 1967-03-20 | 1974-10-24 | Bayer Ag, 5090 Leverkusen | 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin |
DE2117571C3 (de) * | 1971-04-10 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel |
US3985758A (en) * | 1973-02-20 | 1976-10-12 | Yamanouchi Pharmaceutical Co., Ltd. | 1,4-Dihydropyridine derivatives |
US4338322A (en) * | 1975-07-02 | 1982-07-06 | Fujisawa Pharmaceutical Co., Ltd. | 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same |
US4154839A (en) * | 1975-11-05 | 1979-05-15 | Bayer Aktiengesellschaft | 2,6-Dimethyl-3-carboxymethoxy-4-(2-nitrophenyl)-5-carbisobutoxy-1,4-dihydropyridine |
JPS55301A (en) * | 1978-02-14 | 1980-01-05 | Yamanouchi Pharmaceut Co Ltd | 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its preparation |
SE429652B (sv) * | 1978-06-30 | 1983-09-19 | Haessle Ab | 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester |
GB2111978B (en) * | 1981-10-19 | 1985-05-01 | Maruko Pharmaceutical Co | 1 4-dihydropyridine compounds |
DK161312C (da) * | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
WO1983003249A1 (en) * | 1982-03-17 | 1983-09-29 | Yoshitomi Pharmaceutical | 1,4-dihydropyridine-3,5-dicarboxylate derivatives |
EP0094159B1 (en) * | 1982-05-10 | 1990-03-14 | Takeda Chemical Industries, Ltd. | Dihydropyridine derivatives, their production and use |
JPS59225162A (ja) * | 1983-06-03 | 1984-12-18 | Kyowa Hakko Kogyo Co Ltd | 1,4−ジヒドロピリジン誘導体 |
US4656181A (en) * | 1982-11-24 | 1987-04-07 | Cermol S.A. | Esters of 1,4-dihydropyridines, processes for the preparation of the new esters, and medicaments containing the same |
JPS59101423A (ja) * | 1982-12-02 | 1984-06-12 | Takada Seiyaku Kk | 新規なニフエジピン固形製剤 |
US4520112A (en) * | 1983-03-09 | 1985-05-28 | The Johns Hopkins University | Assay method for organic calcium antagonist drugs and a kit for such an assay |
JPS60120861A (ja) * | 1983-12-02 | 1985-06-28 | Otsuka Pharmaceut Co Ltd | ジヒドロピリジン誘導体 |
US4672068A (en) * | 1984-05-04 | 1987-06-09 | Fujirebio Kabushiki Kaisha | Antihypertensive 1,4-dihydropyridines having a conjugated ester |
US4794111A (en) * | 1984-05-23 | 1988-12-27 | Bayer Aktiengesellschaft | Dihydropyridine preparations containing β-blockers |
FI853477L (fi) * | 1984-09-14 | 1986-03-15 | Ciba Geigy Ag | Foerfarande foer framstaellning av karbonylfoereningar. |
US4762950A (en) * | 1985-12-16 | 1988-08-09 | Basf Corporation | Selective oxyalkylaton of N-(2-hydroxyalkyl)-aniline |
US4885284A (en) * | 1986-01-22 | 1989-12-05 | Nissan Chemical Industries Ltd. | Dihydropyridine-5-phosphonic acid cyclic propylene ester |
US5198226A (en) * | 1986-01-30 | 1993-03-30 | Syntex (U.S.A.) Inc. | Long acting nicardipine hydrochloride formulation |
US4940556A (en) * | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
SE8601624D0 (sv) * | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
US4772596A (en) * | 1986-10-09 | 1988-09-20 | Sankyo Company Limited | Dihydropyridine derivatives, their preparation and their use |
JPS6396126A (ja) * | 1986-10-13 | 1988-04-27 | Taisho Pharmaceut Co Ltd | 安定化組成物 |
ATE61588T1 (de) * | 1987-08-03 | 1991-03-15 | Delagrange Lab | 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel. |
SE8703881D0 (sv) * | 1987-10-08 | 1987-10-08 | Haessle Ab | New pharmaceutical preparation |
SU1722252A3 (ru) * | 1988-06-15 | 1992-03-23 | Сименс Аг (Фирма) | Устройство дл вихретокового контрол труб теплообменника с трубами U-образной формы |
US5484789A (en) * | 1989-10-31 | 1996-01-16 | The University Of North Carolina At Chapel Hill | Calcium channel blockers to improve preservation of organs stored for transplantation |
US5209933A (en) * | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
GB2245559A (en) * | 1990-06-25 | 1992-01-08 | Farmos Oy | Bioceramic system for delivery of a bioactive compound. |
US5209993A (en) * | 1990-08-24 | 1993-05-11 | General Motors Corporation | Method of enveloping battery plates |
JP3110794B2 (ja) * | 1991-06-05 | 2000-11-20 | ユーシービージャパン株式会社 | 1,4−ジヒドロピリジン誘導体を含有する製剤 |
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
US5958458A (en) * | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
US5760238A (en) * | 1994-08-29 | 1998-06-02 | Mercian Corporation | 1,4-dihydropyridine derivatives |
JPH10167966A (ja) * | 1996-12-03 | 1998-06-23 | Nippon Chemiphar Co Ltd | 経口持続性製剤 |
ES2125198B1 (es) * | 1997-05-13 | 1999-11-16 | Vita Invest Sa | Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares. |
JP3491506B2 (ja) * | 1997-10-14 | 2004-01-26 | 宇部興産株式会社 | ジヒドロピリジン誘導体の製造法 |
SE9704400D0 (sv) * | 1997-11-28 | 1997-11-28 | Astra Ab | Porous inorganic particles as carriers for drug substances |
US6753011B2 (en) * | 2000-01-14 | 2004-06-22 | Osmotica Corp | Combined diffusion/osmotic pumping drug delivery system |
CZ20031069A3 (cs) * | 2000-10-26 | 2004-05-12 | Pfizeráproductsáinc | Pyrimidin@@Ź@Ź@@trionové inhibitory metaloproteinasy |
MXPA03005886A (es) * | 2000-12-29 | 2005-04-19 | Pfizer Ltd | Derivado de aspartato de amlodipina como antagonista del canal de calcio. |
IL161448A0 (en) * | 2001-10-24 | 2004-09-27 | Sepracor Inc | Method of resolving amlodipine racemate |
-
2001
- 2001-04-10 KR KR1020027013417A patent/KR100756565B1/ko not_active IP Right Cessation
- 2001-04-10 TW TW090108557A patent/TWI246921B/zh not_active IP Right Cessation
- 2001-04-10 EP EP01919870A patent/EP1285655B1/en not_active Expired - Lifetime
- 2001-04-10 DE DE60128683T patent/DE60128683T2/de not_active Expired - Lifetime
- 2001-04-10 AT AT01919870T patent/ATE363281T1/de not_active IP Right Cessation
- 2001-04-10 IL IL15202101A patent/IL152021A0/xx unknown
- 2001-04-10 HU HU0300444A patent/HUP0300444A3/hu unknown
- 2001-04-10 ES ES01919870T patent/ES2287110T3/es not_active Expired - Lifetime
- 2001-04-10 CZ CZ20023353A patent/CZ301790B6/cs not_active IP Right Cessation
- 2001-04-10 PL PL357572A patent/PL201513B1/pl not_active IP Right Cessation
- 2001-04-10 AU AU2001246883A patent/AU2001246883B2/en not_active Ceased
- 2001-04-10 AU AU4688301A patent/AU4688301A/xx active Pending
- 2001-04-10 CN CNB018109438A patent/CN100450483C/zh not_active Expired - Fee Related
- 2001-04-10 CA CA002405046A patent/CA2405046C/en not_active Expired - Fee Related
- 2001-04-10 MX MXPA02010040A patent/MXPA02010040A/es active IP Right Grant
- 2001-04-10 RU RU2002127125/15A patent/RU2239432C2/ru not_active IP Right Cessation
- 2001-04-10 NZ NZ521853A patent/NZ521853A/en not_active IP Right Cessation
- 2001-04-10 WO PCT/JP2001/003087 patent/WO2001076598A1/ja active IP Right Grant
- 2001-04-10 BR BR0109991-4A patent/BR0109991A/pt not_active IP Right Cessation
-
2002
- 2002-09-30 IL IL152021A patent/IL152021A/en not_active IP Right Cessation
- 2002-10-02 ZA ZA200207933A patent/ZA200207933B/en unknown
- 2002-10-10 US US10/268,308 patent/US20030073670A1/en not_active Abandoned
- 2002-10-10 NO NO20024885A patent/NO329943B1/no not_active IP Right Cessation
-
2003
- 2003-04-09 HK HK03102533A patent/HK1050324A1/xx not_active IP Right Cessation
-
2007
- 2007-02-08 US US11/704,122 patent/US20070142442A1/en not_active Abandoned
-
2008
- 2008-12-16 JP JP2008319561A patent/JP2009143923A/ja active Pending
-
2010
- 2010-02-03 US US12/658,202 patent/US20100144697A1/en not_active Abandoned
- 2010-02-03 US US12/658,201 patent/US20100144696A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200207933B (en) | Stabilized pharmaceutical compositions containing calcium channel blockers. | |
RU2002127125A (ru) | Стабилизированная фармацевтическая композиция, содержащая блокатор кальция | |
NO20024176D0 (no) | Farmasöytiske praparater inneholdende 3-amino- azetidinderivater, de nye derivater og deres fremstilling | |
DK1140918T3 (da) | Thrombininhibitorer | |
MEP12708A (en) | Derivatives of n-[phenyl (alkylpiperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics | |
NO20073926L (no) | Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser | |
MEP22008A (en) | Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
PE20080952A1 (es) | Amidas azociclicas fungicidas | |
NO20042146L (no) | Substiuerte 1,4-benzodiazepiner og anvendelse derav | |
MEP12608A (en) | Derivatives of n-[phenyl (pyrrolidine-2-yl) methyl]benzamide and n-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | |
AR034547A1 (es) | Derivados de indolin-2-ona, su utilizacion, procedimiento para su preparacion, composicion farmaceutica que lo contiene, medicamento que consiste en dicho derivado, y un producto que contiene dicho derivado y un antagonista de los receptores de la vasopresina | |
CA2514921A1 (en) | Combined use of olmesartan medoxomil and azelnidipine or amlodipine for the treatment of arteriosclerosis and hypertension | |
NO20060383L (no) | Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister | |
PE20011115A1 (es) | Etanos tri-aril-sustituidos inhibidores de pde4 | |
YU67601A (sh) | 1-arensulfonil-2-aril-pirolidin i derivati piperidina | |
IL155965A0 (en) | Pharmaceutical compositions containing an imidazole-5-carboxyclic acid derivative | |
NO990721L (no) | Stabil ikke-hygroskopisk krystallinsk form av N-[N-N-(4-(piperidin-4-yl)butanoyl)-N-etylglysyl]forbindelser | |
DE69910121D1 (de) | Piperidone als Tachykinin-Hemmer | |
JP4327376B2 (ja) | カルシウムブロッカーを含有する安定化された薬剤組成物 | |
JP2001354565A5 (hu) | ||
TW200503697A (en) | Medicinal compositions containing triazole compounds |